Literature DB >> 22151659

High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality.

P I Johansson1, A M Sørensen, A Perner, K-L Welling, M Wanscher, C F Larsen, S R Ostrowski.   

Abstract

BACKGROUND: Severe injury activates the sympathoadrenal, hemostatic and inflammatory systems, but a maladapted response may contribute to a poor outcome. Soluble CD40L is a platelet-derived mediator that links inflammation, hemostasis and vascular dysfunction.
OBJECTIVES: To investigate the association between the sCD40L level and tissue injury, shock, coagulopathy and mortality in trauma patients.
METHODS: A prospective, observational study of 80 trauma patients admitted to a Level I Trauma Center. Data on demography, biochemistry, Injury Severity Score (ISS) and 30-day mortality were recorded and admission plasma/serum analyzed for sCD40L and biomarkers reflecting sympathoadrenal activation (adrenaline, noradrenaline), tissue/endothelial cell/glycocalyx damage (histone-complexed DNA fragments [hcDNA], Annexin V, thrombomodulin and syndecan-1), coagulation activation/inhibition (PF1.2, TAT-complex, antithrombin, protein C, activated protein C, sEPCR, TFPI, von Willebrand factor [VWF], fibrinogen and factor [F] XIII), fibrinolysis (D-dimer, tissue plasminogen activator [tPA] and plasminogen activator inhibitor-1 [PAI-1]) and inflammation (interleukin-6 [IL-6] and sC5b-9). We compared patients stratified by median sCD40L level and investigated predictive values of sCD40L for mortality.
RESULTS: High circulating sCD40L was associated with enhanced tissue and endothelial damage (ISS, hcDNA, Annexin V, syndecan-1 and sTM), shock (pH, standard base excess), sympathoadrenal activation (adrenaline) and coagulopathy evidenced by reduced thrombin generation (PF1.2), hyperfibrinolysis (D-dimer), increased activated partial thromboplastin time (APTT) and inflammation (IL-6) (all P < 0.05). A higher ISS (P = 0.017), adrenaline (P = 0.049) and platelet count (P = 0.012) and lower pH (P =0.002) were associated with higher sCD40L by multivariate linear regression analysis. High circulating sCD40L (odds ratio [OR] 1.84 [95% CI 1.05-3.23], P = 0.034), high age (P = 0.002) and low Glasgow Coma Score (GCS) pre-hospital (P = 0.002) were independent predictors of increased mortality.
CONCLUSIONS: High early sCD40L levels in trauma patients reflect tissue injury, shock, coagulopathy and sympathoadrenal activation and predict mortality. As sCD40L has pro-inflammatory activity and activates the endothelium, sCD40L may be involved in trauma-induced endothelial damage and coagulopathy.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22151659     DOI: 10.1111/j.1538-7836.2011.04589.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  23 in total

1.  Early hemostatic responses to trauma identified with hierarchical clustering analysis.

Authors:  N J White; D Contaifer; E J Martin; J C Newton; B M Mohammed; J L Bostic; G M Brophy; B D Spiess; A E Pusateri; K R Ward; D F Brophy
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

2.  Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients.

Authors:  Hunter B Moore; Ernest E Moore; Ioannis N Liras; Eduardo Gonzalez; John A Harvin; John B Holcomb; Angela Sauaia; Bryan A Cotton
Journal:  J Am Coll Surg       Date:  2016-01-22       Impact factor: 6.113

Review 3.  THE GLYCOCALYX AND TRAUMA: A REVIEW.

Authors:  Andreia Z Chignalia; Feliz Yetimakman; Sarah C Christiaans; Sule Unal; Benan Bayrakci; Brant M Wagener; Robert T Russell; Jeffrey D Kerby; Jean-Francois Pittet; Randal O Dull
Journal:  Shock       Date:  2016-04       Impact factor: 3.454

Review 4.  Trauma-Induced Coagulopathy: An Institution's 35 Year Perspective on Practice and Research.

Authors:  E Gonzalez; E E Moore; H B Moore; M P Chapman; C C Silliman; A Banerjee
Journal:  Scand J Surg       Date:  2014-04-30       Impact factor: 2.360

5.  Prehospital Resuscitation of Traumatic Hemorrhagic Shock with Hypertonic Solutions Worsens Hypocoagulation and Hyperfibrinolysis.

Authors:  Matthew J Delano; Sandro B Rizoli; Shawn G Rhind; Joseph Cuschieri; Wolfgang Junger; Andrew J Baker; Michael A Dubick; David B Hoyt; Eileen M Bulger
Journal:  Shock       Date:  2015-07       Impact factor: 3.454

Review 6.  The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology.

Authors:  Stefano Giordano; Luca Spiezia; Elena Campello; Paolo Simioni
Journal:  Intern Emerg Med       Date:  2017-05-05       Impact factor: 3.397

Review 7.  Hemorrhagic blood failure: Oxygen debt, coagulopathy, and endothelial damage.

Authors:  Nathan J White; Kevin R Ward; Shibani Pati; Geir Strandenes; Andrew P Cap
Journal:  J Trauma Acute Care Surg       Date:  2017-06       Impact factor: 3.313

8.  Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats.

Authors:  Francis J Castellino; Michael P Chapman; Deborah L Donahue; Scott Thomas; Ernest E Moore; Max V Wohlauer; Braxton Fritz; Robert Yount; Victoria Ploplis; Patrick Davis; Edward Evans; Mark Walsh
Journal:  J Trauma Acute Care Surg       Date:  2014-05       Impact factor: 3.313

9.  A principal component analysis of coagulation after trauma.

Authors:  Matthew E Kutcher; Adam R Ferguson; Mitchell J Cohen
Journal:  J Trauma Acute Care Surg       Date:  2013-05       Impact factor: 3.313

10.  Prehospital plasma is associated with distinct biomarker expression following injury.

Authors:  Danielle S Gruen; Joshua B Brown; Francis X Guyette; Yoram Vodovotz; Pär I Johansson; Jakob Stensballe; Derek A Barclay; Jinling Yin; Brian J Daley; Richard S Miller; Brian G Harbrecht; Jeffrey A Claridge; Herb A Phelan; Matthew D Neal; Brian S Zuckerbraun; Timothy R Billiar; Jason L Sperry
Journal:  JCI Insight       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.